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Abstract: Plasma amyloid-beta (Aβ) has long been investigated as a blood biomarker candidate for
Cerebral Amyloid Angiopathy (CAA), however previous findings have been inconsistent which
could be attributed to the use of less sensitive assays. This study investigates plasma Aβ alterations
between pre-symptomatic Dutch-type hereditary CAA (D-CAA) mutation-carriers (MC) and non-
carriers (NC) using two Aβ measurement platforms. Seventeen pre-symptomatic members of a
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D-CAA pedigree were assembled and followed up 3–4 years later (NC = 8; MC = 9). Plasma Aβ1-40
and Aβ1-42 were cross-sectionally and longitudinally analysed at baseline (T1) and follow-up (T2)
and were found to be lower in MCs compared to NCs, cross-sectionally after adjusting for covariates,
at both T1(Aβ1-40: p = 0.001; Aβ1-42: p = 0.0004) and T2 (Aβ1-40: p = 0.001; Aβ1-42: p = 0.016)
employing the Single Molecule Array (Simoa) platform, however no significant differences were
observed using the xMAP platform. Further, pairwise longitudinal analyses of plasma Aβ1-40
revealed decreased levels in MCs using data from the Simoa platform (p = 0.041) and pairwise
longitudinal analyses of plasma Aβ1-42 revealed decreased levels in MCs using data from the xMAP
platform (p = 0.041). Findings from the Simoa platform suggest that plasma Aβmay add value to a
panel of biomarkers for the diagnosis of pre-symptomatic CAA, however, further validation studies
in larger sample sets are required.
Keywords: amyloid-beta; plasma amyloid-beta; blood biomarkers; cerebral amyloid angiopathy;
early diagnosis; hereditary cerebral haemorrhage with amyloidosis—Dutch type; single molecule
array platform
1. Introduction
Sporadic Cerebral Amyloid Angiopathy (CAA) is a leading cause of intracerebral
haemorrhage (ICH) and vascular dementia in older adults and is associated with the
accumulation of amyloid-β (Aβ) in the cerebral vasculature [1]. The prognosis after CAA-
related ICH is poor, with mortality rates reaching as high as 50% or more [2]. CAA
pathology is widely seen in patients with Alzheimer’s disease (AD), of whom around
80% exhibit CAA co-morbidity [3]. In addition, the co-presence of CAA in AD, even
in the absence of overt ICH, may negatively influence the progression of AD-related
neurodegeneration [4,5]. Hence, the ability to diagnose CAA at its earliest stages is crucial.
The Boston criteria aids with the diagnosis of possible and probable CAA [6,7], how-
ever, a definitive CAA diagnosis can only be performed by neuropathological examination
post-mortem [7]. Early diagnosis using pre-symptomatic CAA markers will provide clin-
icians with an opportunity to inform patients on the potential risks of thrombolysis or
anticoagulation therapy and, treating or lowering other modifiable risk-factors for ICH and
vascular dementia such as hypertension, diabetes, hypercholesterolaemia and smoking.
The Dutch-type hereditary Cerebral Amyloid Angiopathy (D-CAA) also known as
hereditary cerebral haemorrhage with amyloidosis Dutch type (HCHWA-D) is a rare
autosomal dominant disorder and occurs due to the presence of a guanine to cytosine
transversion point mutation on codon 693 of the amyloid precursor protein gene (APP
E693Q) [8]. The neuropathological hallmark of this mutation is the accumulation of
abnormal Aβ (Aβ E22Q) in the cerebral vasculature along with diffuse cerebral plaques,
and clinical manifestations of this mutation are recurrent haemorrhagic strokes during mid-
life, with dementia usually developing after the first stroke [9,10]. Due to 100% penetrance
of the D-CAA mutation if inherited, pre-symptomatic individuals carrying the D-CAA
mutation can be identified by genetic analysis, and therefore provide an invaluable human
model to study pre-symptomatic biomarkers that may be generalizable to sporadic CAA.
Previous studies evaluated cerebrospinal fluid (CSF) Aβ1-40 and Aβ1-42 and brain
Aβ load (via positron emission tomography, PET) as potential CAA markers in D-CAA and
sporadic CAA individuals. Lower CSF Aβ1-40 and Aβ1-42 levels and higher PET-Aβ signal
were observed in pre-symptomatic and symptomatic D-CAA mutation carrier individuals
(MCs) and sporadic CAA individuals compared to D-CAA non-carrier individuals (NCs)
and controls, respectively [11–13]. However, due to the invasive nature of a lumbar
puncture and the costs involved with PET-Aβ imaging, potential blood-based biomarkers
for pre-symptomatic CAA need to be investigated [14], as a less invasive and cost-effective
measure to detect pre-symptomatic CAA.
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Therefore, the aim of the current study was to investigate plasma Aβ1-40 and Aβ1-42
concentrations as potential blood-based biomarkers for CAA. Previous findings have been
inconsistent regarding plasma Aβ alterations in CAA [15–17], which could be attributed to less
sensitive assays employed in the past for the measurement of plasma Aβ1-40 and Aβ1-42.
To address the previous limitations regarding Aβ assay sensitivity, the current study
employed the ultrasensitive Single Molecule Array (Simoa) platform to quantitate and
compare plasma Aβ1-40 and Aβ1-42 concentrations in pre-symptomatic MCs and NCs
from the same pedigree, cross-sectionally at two timepoints. Additionally, the current study
also investigated changes in plasma Aβ1-40 and Aβ1-42 concentrations between MCs and
NCs, longitudinally. Further, plasma Aβ1-40 and Aβ1-42 concentrations measured using
the Simoa technology platform were compared against observations using the xMAP
technology platform, between MCs and NCs. We hypothesised that plasma Aβ1-40 and
Aβ1-42 concentrations would be lower in the MCs compared to the NCs cross-sectionally
and would decrease in MCs longitudinally.
2. Materials and Methods
2.1. Participants
Participants were enrolled in the Dominantly Inherited Alzheimer Network (DIAN)
study at Edith Cowan University, Western Australia. All participants in the study were
from the same APP E693Q D-CAA pedigree (n = 18) whose ancestors migrated from the
Netherlands to Australia. Upon DNA testing, ten participants were found to be positive for
the mutation while eight were negative. One MC had a history of stroke and was excluded
from the current study in order to utilise a purely pre-symptomatic cohort in the present
study. Therefore, eight NCs and nine MCs were included in the current study at baseline
(Timepoint 1, T1). Seven NCs and eight MCs from the participants studied at T1 were
followed up approximately three (NCs = 6, MCs = 7) to four years (NC = 1, MC = 1) later
(Timepoint 2, T2). Blood samples were available for all participants included in the study
at T1 and T2, while CSF samples were available for seven NCs and six MCs at T1, and
five NCs and three MCs at T2. The study was approved by the human research ethics
committees at Macquarie University, Edith Cowan University, Hollywood Private Hospital
and Washington University. All participants provided informed written consent.
2.2. Plasma Aβ Measurements and APOE ε4 Genotype Status
Blood processing for plasma collection was performed within 3 h of blood draw, in the
morning under fasting conditions, and stored at −80 ◦C. Plasma Aβ concentrations were
measured employing the Amyblood test on the Simoa platform (HDx instrument, Quan-
terix) using N-terminal-specific monoclonal antibodies provided by ADx NeuroSciences,
as described previously [18,19]. Briefly, for Aβ1-40, C-terminal-specific ADx103 (2G3,
Aβx-40) was used as the capture antibody and N-terminal-specific ADx101 (3D6, Aβ1-x)
was used as the detector antibody. For Aβ1-42, C-terminal-specific ADx102 (21F12, x-42)
was used as the capture antibody and N-terminal-specific ADx101 was used as the detector
antibody. The percent coefficients of variation (CV) of the three quality control samples
ranged between 0–4% and 0–19% for Aβ1-40 and Aβ1-42, respectively. The apolipoprotein
E (APOE) ε4 genotype status, used as a dichotomous variable (presence/absence), of each
study participant was accessed from the DIAN database [20].
2.3. Neuropsychological Assessments
Neuropsychological data were obtained from the DIAN database. The Mini Mental State
Examination (MMSE) was used as a measure of general cognitive function [21], and the Clinical
Dementia Rating (CDR) scale scores, comprising semi-structured interviews for assessing
dementia severity [22], were utilised as measures of dementia status within the study.
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2.4. Assessment of CSF Aβ Concentration and PET Aβ Load
CSF Aβ (Aβ1-40, Aβ1-42) concentrations were obtained from the DIAN database. CSF
Aβ1-40 and Aβ1-42 concentrations were measured using INNOTEST β-AMYLOID(1-40)
and INNOTEST β-AMYLOID(1-42) (Fujirebio, Ghent, Belgium) as described previously [20].
Brain Aβ load measured using PET coupled with the ligand 11C-Pittsburgh Compound
B, represented by standard uptake value ratios (SUVR), was accessed from the DIAN
database. The SUVR utilised in the current study was calculated with FreeSurfer in the
precuneus as the region of interest with the cerebellar grey matter as the reference region,
as described previously [23].
2.5. Statistical Analysis
Descriptive statistics including means and standard deviations, or proportions were
calculated for NCs and MCs, with comparisons employing general linear models or Fisher’s
exact test as appropriate. General linear models were employed to compare continuous
variables (plasma Aβ1-40 and Aβ1-42) between NCs and MCs, before and after adjustment
for the covariates age, sex and APOE ε4 carrier status both cross-sectionally (univariate
analyses) and longitudinally (repeated measures). Dependent variables were natural log
transformed to better approximate normality and variance homogeneity as required. All
analyses were carried out using IBM SPSS (Version 26).
3. Results
3.1. Participant Characteristics
Participant characteristics are presented in Table 1. No significant differences in
participant demographics, APOE ε4 allele frequency, cognition or history of stroke were
present between NCs and pre-symptomatic MCs at T1 and T2.
Table 1. Participant characteristics at T1 and T2. Characteristics including sex, age, expected years to symptom onset (EYO)
based on age at symptom onset of biological mutation carrier parent, APOE ε4 status, Mini-Mental State Examination (MMSE)
scores, Clinical Dementia Rating (CDR) scale scores, history of stroke, cerebrospinal fluid (CSF) Aβ1-40 levels, CSF Aβ1-42
levels and brain Aβ load signal have been compared between Dutch-type hereditary cerebral amyloid angiopathy (D-CAA)
mutation non-carriers (NCs) and pre-symptomatic carriers (MCs) from the same pedigree at T1 and T2. Fisher’s exact test or
linear models were employed as appropriate. CSF Aβ1-42 and Aβ1-40 were measured using the INNOTEST β-AMYLOID(1-40)
and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebio, Ghent, Belgium). Brain Aβ load was measured via positron emission
tomography and is presented as the standard uptake value ratio (SUVR) of the ligand, 11C Pittsburgh Compound B, uptake in
the precuneus as the region of interest, with the cerebellar grey matter as the reference region. p a represents p-values adjusted
for age, sex and APOE ε4 carrier status. p < 0.05 was considered significant and are presented in bold font.
D-CAA NC D-CAA MC p p a
T1
N 8 9 - -
Sex (M/F) 3/5 3/6 1.00 -
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 -
EYO (years; Mean ± SD) −6.09 ± 6.43 −5.27 ± 4.30 0.759 -
APOE ε4 (%) 37.5 22.2 0.620 -
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 -
CDR global = 0 (%) 100 100 - -
Stroke (%) 0 0 - -
CSF Aβ1-40 (pg/mL; Mean ± SD) # 9882.92 ± 3076.97 6971.35 ± 1088.65 0.051 0.039
CSF Aβ1-42 (pg/mL; Mean ± SD) # 618.63 ± 206.81 311.67 ± 154.85 0.012 0.007
Brain Aβ load (SUVR, Mean ± SD) 0.994 ± 0.064 1.268 ± 0.248 0.009 0.011
T2
N 7 8 - -
Sex (M/F) 2/5 2/6 1.00 -
Age (Mean ± SD) 46.57 ± 7.21 46.25 ± 4.65 0.830 -
EYO (years; Mean ± SD) −2.97 ± 7.02 −2.12 ± 4.75 0.785 -
APOE ε4 (%) 42.86 25 0.608 -
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 -
CDR global = 0 (%) 100 100 - -
Stroke (%) 0 0 - -
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - -
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - -
Brain Aβ load (SUVR, Mean ± SD) 1.06 ± 0.034 1.35 ± 0.25 0.009 0.001
# CSF parameters are only presented for seven NCs and six MCs at T1, and for three NCs and five MCs at T2, due to CSF sample
unavailability. Statistical comparisons of CSF parameters between NCs and MCs were not conducted for T2 due to the small sample size.
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3.2. Cross-Sectional Differences in CSF Aβ and Brain Aβ between D-CAA Mutation Non-Carriers
and Carriers
CSF Aβ1-40 and Aβ1-42 concentrations were observed to be significantly lower in the
MCs compared to NCs at T1, after adjusting for covariates age, sex and APOE ε4 genotype,
as expected, and mean CSF Aβ1-40 and Aβ1-42 levels were lower in the MCs compared to
the NCs at T2 (statistical analyses were not conducted for CSF Aβ1-40 and Aβ1-42 levels at
T2 due to the small CSF sample size at this visit, Table 1). Brain Aβ load assessed via PET
was significantly higher in the MCs compared to the NCs at T1 and T2 (Table 1).
3.3. Cross-Sectional Differences in Plasma Aβ between D-CAA Mutation Non-Carriers and
Carriers Employing the Ultrasensitive Simoa Technology
Cross-sectional analyses revealed that plasma Aβ1-40 and Aβ1-42 levels were sig-
nificantly lower in the MCs compared to the NCs at both timepoints, T1 and T2, before
and after adjusting for potential confounding variables, age, sex and APOE ε4 genotype
(p < 0.05, Figure 1, Table 2).
Figure 1. Comparison of plasma Aβ1-40 and Aβ1-42 levels between D-CAA mutation non-carriers and carriers at T1 and
T2. Plasma Aβ levels measured using the Amyblood assay on the ultrasensitive Single Molecule Array (Simoa) platform
were compared between D-CAA mutation non-carriers (NC) and carriers (MC) at T1 (NC = 8, MC = 9) and T2 (NC = 7,
MC = 8, using general linear models. * p < 0.05, ** p < 0.01, *** p < 0.001, adjusted for age, sex and APOE ε4 carrier status.
p < 0.05 was considered significant.
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Table 2. Cross-sectional comparison of plasma Aβ levels between pre-symptomatic D-CAA mutation
carriers and non-carriers measured on the ultrasensitive Simoa platform. Plasma Aβ levels were
compared between D-CAA mutation carriers and non-carriers using general linear models separately
at T1 and T2. Data are presented at T1 and T2. Data are presented as Mean ± SD in pg/mL. p a
represents p-values adjusted for age, sex and APOE ε4 carrier status.
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 D-CAA NC D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-40  66.30 ± 7.83 53.87 ± 6.07 0.002 0.001 
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Aβ1-42 16.85 ± 4.96 11.16 ± 2.79 0.020 ⱡ 0.016 
  
represents p-values obtained
from natural log transformed Aβ1-40 or Aβ1-42 concentrations to better approximate normality.
p-values < 0.05 were considered significant and are presented in bold font.
D-CAA NC D-CAA MC p p a
T1 n= 8 n= 9
Aβ1-40 66.30 ± 7.83 53.87 ± 6.07 0.002 0.001
Aβ1-42 18.02 ± 2.01 11.31 ± 3.02 0.00009 0.0004
T2 n= 7 n= 8
Aβ1-40 65.04 ± 14.45 46.92 ± 6.93 0.008
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CSF Aβ1-42 (pg/mL; Mean ± SD) # 618.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load (SUVR, Mean ± SD) 0.994 ± 0.064 1.268 ± 0.248 0.009 0.011 
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EYO (years; Me n ± SD)  −2.97 ± 7.02 −2.12 ± 4.75 0.785 - 
APOE ε4 (%) 42.86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
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Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load (SUVR, Mean ± SD) 1.06 ± 0.034 1.35 ± 0.25 0.009 0.001 
# CSF parameters are only presented for seven NCs and six MCs at T1, and for three NCs and five MCs at T2, due to CSF 
sample unavailability. Statistical comparisons of CSF parameters between NCs and MCs were not conducted for T2 due 
to the small sample size. 
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EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
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Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 9882.92 ± 3076.97 6971.35 ± 1088.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 618.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
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EYO (year ; Mean ± SD)  −2.97 ± 7.0  − .12 ± 4.75 0.785 - 
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3.4. Cross-Sectional Comparison of Plasma Aβ between D-CAA Mutation Non-Carriers and
Carriers Employing xMAP Technology
Cross-sectional analyses did not show a significant difference in plasma Aβ1-40 and
Aβ1-42 levels between MCs and NCs, after adjusting for covariates age, sex and APOE ε4
genotype at both T1 and T2, although mean concentrations of both Aβ1-40 and Aβ1-42
were lower in the MCs compared to the NCs and in line with the ultrasensitive Simoa
technology, Aβ1-42 levels were significantly lower in the MCs compared to the NCs at T2
before adjusting for covariates (Supplementary Figure S1, Supplementary Table S1).
3.5. Longitudinal Changes in Plasma Aβ Concentrations Employing the Ultrasensitive Simoa
Technology
Longitudinal analyses revealed that Aβ1-40 concentrations decreased over time (T1 to
T2) with a trend towards significance (p = 0.057), before adjusting for covariates, age, sex
and APOE ε4 genotype, wherein pairwise comparisons showed significantly decreased
mean plasma Aβ1-40 concentrations in MCs (p = 0.045, Table 3). After adjusting for
covariates, age, sex and APOE ε4 genotype, longitudinal analyses revealed that Aβ1-40
concentrations significantly decreased over time (T1 to T2, p = 0.028), wherein a pairwise
comparison showed significantly decreased mean plasma Aβ1-40 concentrations in MCs
(p = 0.041, Table 3). No statistically significant effect of time on plasma Aβ1-40 in NCs
was observed before or after adjusting for covariates (Table 3). Time * Mutation status
interaction revealed no significant differences in plasma Aβ1-40 changes between MCs
and NCs, either before or after adjusting for potential confounding variables age, sex and
APOE ε4 genotype (Figure 2, Table 3) which could be attributed to the modest sample size.
No statistically significant effect on plasma Aβ1-42 concentrations was observed over
time (T1 to T2), including pairwise comparisons in MCs or NCs, or Time * Mutation status
interactions, before and after adjusting for covariates, age, sex and APOE ε4 genotype
(Table 3).
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Table 3. Longitudinal comparison of plasma Aβ levels between pre-symptomatic D-CAA mutation carriers and non-carriers. Plasma Aβ levels were measured on the Simoa platform and
were compared between D-CAA mutation carriers (MC) and non-carriers (NC) using repeated measures analyses at T1 and T2, before and after adjustment for covariates age, sex and
APOE ε4 carrier status, using a factorial design (all two-way interactions with time included). Data are presented as Mean ± SD in pg/mL.
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APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
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Stroke (%) 0 0 - - 
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Aβ1-40 67.01 ± 8.17 65.04 ± 14.45 52.86 ± 5.62 46.92 ± 6.93 0.057
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(EYO) based on age at symptom onset of biological mutation carrier parent, APOE ε4 status, Mini-Mental State Examina-
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angiopathy (D-CAA) mutation non-carriers (NCs) and pre-symptomatic carriers (MCs) from the same pedigree at T1 and 
T2. Fisher’s exact test or linear models were employed as appropriate. CSF Aβ1-42 and Aβ1-40 were measured using the 
INNOTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebio, Ghent, Belgium). Brain Aβ load was 
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reference region. p a represents p-values adjusted for age, sex and APOE ε4 carrier status. p < 0.05 was considered signifi-
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APOE ε4 (%) 37.5 22.2 0.620 - 
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T2 
N 7 8 - - 
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to the small sample size. 
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Table 1. P rticipant characteristics at T1 and T2. Characteristics including s x, age, expected years to symptom onset 
(EYO) based on age at symptom onset of b logical mutation carrier parent, APOE ε4 status, Mini-Mental State Examina-
tion (MMSE) scores, Clinical Dementia R ting (CDR) cale scores, histo y of troke, cerebrospinal fluid (CSF) Aβ1-40 lev-
els, CSF Aβ1-42 levels an brain Aβ load signal hav  be n compared between Dutch-type hereditary cerebral amyloid 
angiopathy (D-CAA) mutation non-carrie s (NCs) and pre-symptomatic carriers (MCs) from th same pe igree at T1 and 
T2. Fisher’s xact test or linear odels were employed as appropriate. CSF Aβ1-42 and Aβ1-40 were measured using the 
INNOTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebio, Ghent, Belgium). Brain Aβ load was 
measured via positron emission tomog aphy and is prese ted as the standard uptake value ratio (SUVR) of the ligand, 
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cant and are prese ed in bold font. 
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T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 882.92 ± 3076.  971.35 ± 1 88.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 618.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load ( UVR, Mean ± SD) 0.994 ± 0.064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46.57 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.7 0.785 - 
APOE ε4 (%) 42.86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load ( UVR, Mean ± SD) 1.06 ± 0.034 1.35 ± 0.25 0.009 0.001 
# CSF paramet rs are only pr sented for seven NCs and six MCs at T1, and for thr e NCs and five MCs at T2, due to CSF 
sample unava lability. Statistical comparisons of CSF parameters between NCs and MCs were n t conducted for T2 due 
to the small sample size. 
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carrie s and non-carriers using general linear models separately at T1 and T2. Data are presented at T1 and T2. Data are 
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els, CSF Aβ1-42 levels an brain Aβ load signal hav  be n compared between Dutch-type hereditary cerebral amyloid 
a giop thy (D-CAA) mutation non-carrie s (NCs) and pre-sy ptomatic carr e s (MCs) from th same pe igree at T1 and 
T2. Fisher’s xact test or line r dels were employed as appropriate. CSF Aβ1-42 a d Aβ1-40 were measured using the 
INNOTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebi , Ghent, Belgium). Brain Aβ load was 
measured via positron emission tomog aphy nd is prese ted as the standard uptake value ratio (SUVR) of the ligand, 
11C Pittsburgh Compou d B, uptake i  the precuneus as th  region of inter st, with th  cereb llar grey matter as the 
referenc  region. p a represent  p-values adjusted fo age, ex nd APOE ε4 carrier st tus. p < 0.05 was considered signifi-
cant and are prese ed in bold font. 
 D-C A NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 882.92 ± 3076.  971.35 ± 1 88. 5 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 6 8.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load ( UVR, Mean ± SD) 0.994 ± 0.064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46. 7 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.7 0.785 - 
APOE ε4 (%) 42.86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load ( UVR, Mean ± SD) 1.06 ± 0.034 1.35 ± 0.25 0.009 0.001 
# CSF paramet rs are only pr sented for seven NCs and six MCs at T1, and for thr NCs and five MCs at T2, due to CSF 
s mple unava lability. Statistical comparisons of CSF paramet rs be ween NCs and MCs were n t conducted for T2 due 
to the small sample size. 
Table 2. Cr s -sectio al compariso  of plas a Aβ lev l  between pre-sympto a ic D-CAA mutatio  carriers and non-
c rriers measured on th ultrasensitive Simoa platfor . Plasma Aβ levels were compared between D-CAA mutation 
carrie s and non-carriers using general linear models separately at T1 and T2. Data re p sented at T1 and T2. Data are 
presented as Mean ± SD in pg/mL. p a represent  p-values adjusted for age, ex nd APOE ε4 carri r status. ⱡ represents p-
values ob ain from tural log trans med Aβ1-40 or Aβ1-42 c ncent ations o be ter approximate no mality. p-values 
<0.05 were consider significant and are prese ed in bold font. 
 D-CAA N  D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-40  66.30 ± 7.83 53.87 ± 6.07 0.0 2 0.001 
Aβ1-42 18.02 ± 2.01 11.31 ± 3.02 0.000 9 0.0004 
T2 n = 7 n = 8  





Aβ1- 2 16.85 ± 4.96 11 16 ± 2.79 0.020 ⱡ 0.016 
  
0.028
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Table 1. P rticipant characteristics at T1 a d T2. Ch acteris ics including s x, age, expected years to symptom onset 
(EYO) based on age at symptom ons t of b logical muta ion carrier pare t, APOE ε4 status, Mini-Mental State Examina-
tion (MMSE) scores, Cl nical Dementia R ting (CDR) cal scores, histo y of troke, cerebrospinal fluid (CSF) Aβ1-40 lev-
els, CSF Aβ1-42 levels an brain Aβ load signal hav  be n compared between Dutch-type hereditary cerebral amyloid 
a giop thy (D-CAA) u ation non-carrie s (NCs) and pre-sy ptomatic carr e s (MCs) from th same pe igree at T1 and 
T2. Fisher’s xact test or line r dels were employed as appropriate. CSF Aβ1-42 a d Aβ1-40 were measured using the 
INNOTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebi , Ghent, Belgium). Brain Aβ load was 
measured via positron mission tomog aphy nd is prese ted as the st ard uptake value ratio (SUVR) of the ligand, 
11C Pittsburgh Compound B, uptake i  the precun us as th  region of inter st, with th  cereb llar grey matter as the 
referenc  r gion. p a represent  p-values adjusted fo age, ex nd APOE ε4 carrier st tus. p < 0.05 was considered signifi-
cant and are prese ed in bold font. 
 D-C A NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 882.92 ± 3076.  971.35 ± 1 88.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 6 8.63 ± 206.81 311.6  ± 154.85 0.012 0.007 
Brain Aβ load ( UVR, Mean ± SD) 0.994 ± .064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46. 7 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.7 0.785 - 
APOE ε4 (%) 42.8  25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1. 8 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load ( UVR, Mean ± SD) 1.06 ± 0. 34 1.35 ± 0.25 0.009 0.001 
# CSF p ramet rs are only pr sented for seven NCs and six MCs at T1, and for thr NCs and five MCs at T2, due to CSF 
mple un v lability. Statistical comparisons of CSF paramet rs be ween NCs and MCs were n t conducted for T2 due 
to the small sample size. 
T ble 2. Cr s -sectio al compariso  of plas a Aβ lev l  betw en pre-sympto a ic D-CAA mutatio  carriers and non-
c rriers measured on th ultrasensitive Simoa platfor . Plasma Aβ levels were compared between D-CAA mutation 
carrie s and non-carriers using general linea  mod ls separ tely at T1 and T2. Data re p sented at T1 and T2. Data are 
presented a Mean ± SD in pg/mL. p a represent  p-values adjust d for age, ex nd APOE ε4 carri r status. ⱡ represents p-
val es ob ain f om atur l log transf med Aβ1-40 or Aβ1-42 c ncent ations o be ter app oximate normality. p-values 
<0.05 were consider significant and are prese ed in bold font. 
 D- AA N  D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-40  6.30 ± 7.83 53.87 ± 6.07 0.0 2 0.001 
Aβ1-42 18.02 ± 2.01 11.31 ± 3.02 0.000 9 0.0004 
T2 n = 7 n = 8  





Aβ1- 2 16.85 ± 4.96 11 16 ± 2.79 0.020 ⱡ 0.016 
  
0.227
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Table 1. P rticipant characteristics at T1 a d T2. Ch act ris ics including s x, age, expected years to symptom onset 
(EYO) based on age at symptom ons t of b logical muta on carrier pare t, APOE ε4 status, Mini-Mental State Examina-
ti n (MMSE) scores, Cl nical Deme tia R ting (CDR) cal scores, histo y of troke, cerebrospinal fluid (CSF) Aβ1-40 lev-
els, CSF Aβ1-42 levels an brain Aβ load signal h v  be n compared between Dutch-type hereditary cerebral amyloid 
a giop thy (D-CAA) u ation non-carrie s (NCs) and pre-sy ptomatic carr e s (MCs) from th same pe igree at T1 and 
T2. Fisher’s xact test or line r dels were employed as appropriate. CSF Aβ1-42 a d Aβ1-40 were measured using the 
INNOT ST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebi , Ghent, Belgium). Brain Aβ load was 
measured vi  positron mission tomog aphy nd is prese ted as the st ard uptake value ratio (SUVR) of the ligand, 
11C Pittsburgh Compound B, uptake i  the precuneus as th  region of inter st, with th  cereb llar grey matter as the 
referenc  r gion. p a represent  p-values djuste  fo age, ex nd APOE ε4 carrier st tus. p < 0.05 was considered signifi-
cant and are prese ed in bold font. 
 D-C A NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 882.92 ± 3076.  971.35 ± 1 88.65 0.051 0.039 
CSF Aβ -42 (pg/mL; Mean ± SD) # 6 8.63 ± 206.81 311.67 ± 154.85 0.012 0.0  
Brain Aβ load ( UVR, Mean ± SD) .994 ± .064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46. 7 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.7 0.785 - 
APOE ε4 (%) 42.8  25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1. 8 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load ( UVR, Mean ± SD) 1.06 ± 0. 34 1.35 ± 0.25 0.009 0.001 
# CSF p ramet rs are only pr sented for seven NCs and six MCs at T1, and for thr NCs and five MCs at T2, due to CSF 
mple un v lability. Statistical comparisons of CSF param t rs be ween NCs and MCs were n t conducted for T2 due 
to the small sample size. 
T bl  2. Cr s -sectio al compariso  of plas a Aβ lev l  betw en pre-sympto a ic D-CAA mutatio  carriers and non-
c rriers measured on th ultrasensi iv  Simoa platfor . Plasma Aβ levels were compared between D-CAA mutation 
carrie s and non-carriers using g eral linea  mod ls separ tely at T1 and T2. Data re p sented at T1 and T2. Data are 
pres nted a Mean ± SD in pg/mL. p a represent  p-values adjust d for age, ex nd APOE ε4 carri r status. ⱡ represents p-
values ob ain from atural log transf med Aβ1-40 or Aβ1-42 c nce t ation  o be ter approximate normality. p-values 
<0.05 were consider significant and are prese ed in bold font. 
 D- AA N  D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-40  6.30 ± 7.83 53.87 ± 6.07 0.0 2 0.001 
Aβ1-42 18.02 ± 2.01 11.31 ± 3.02 0.000 9 0.0004 
T2 n = 7 n = 8  





Aβ1- 2 16.85 ± 4.96 11 16 ± 2.79 0.020 ⱡ 0.016 
  
0.041
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Table 1. P rticipant charac eristics at T1 a d T2. Ch act ris ics including s x, age, expected years to symptom onset 
(EYO) based on age at symp om ons t of b logical muta on carrier pare t, APOE ε4 status, Mini-Mental State Examina-
ti n (MMSE) sc res, Cl nical Deme tia R ting (CDR) cal scores, histo y of troke, cerebrospinal fluid (CSF) Aβ1-40 lev-
els, CSF Aβ1-42 lev ls an brain Aβ load signal h v  be n compared between Dutch-type hereditary cerebral amyloid 
a giop thy (D-CAA) u ation non-c rrie s (NCs) and pre-sy ptomatic carr e s (MCs) from th same pe igree at T1 and 
T2. Fisher’s xact test or line r dels were employed as appropriate. CSF Aβ1-42 a d Aβ1-40 were measured using the 
INNOT ST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebi , Ghent, Belgium). Brain Aβ load was 
meas red vi  posit on mission tomog aphy nd is prese ted as the st ard uptake value ratio (SUVR) of the ligand, 
11C Pittsburgh Compound B, uptake i  the precuneus as th  region of inter st, with th  cereb llar grey matter as the 
refe enc  r gion. p a represent  p-values djuste  fo age, ex nd APOE ε4 carrier st tus. p < 0.05 was considered signifi-
cant and are prese ed in bold font. 
 D-C A NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 882.92 ± 3076.  971.35 ± 1 88.65 0.051 0.039 
CSF Aβ -42 (pg/mL; Mean ± SD) # 6 8.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain β load ( UVR, Mean ± SD) .994 ± .064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46. 7 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.7 0.785 - 
APOE ε4 (%) 42.8  25 0.608 - 
MMSE (Mea ± SD) 28.71 ± 1. 8 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load ( UVR, Mean ± SD) 1.06 ± 0. 34 1.35 ± 0.25 0.009 0.001 
# CSF p ramet rs are only pr sente for seven NCs and six MCs at T1, and for thr NCs and five MCs at T2, due to CSF 
mple un v lability. Statistical comparisons of CSF param t rs be ween NCs and MCs were n t conducted for T2 due 
to the small sample size. 
T bl  2. Cr s -sectio al c mp riso of plas a Aβ lev l  betw en pre-sympto a ic D-CAA mutatio  carriers and non-
c rri s measure  on th ultrasensi iv  Simoa platfor . Plasma Aβ levels were compared between D-CAA mutation 
carrie s nd non-carriers using g eral line  mod ls separ tely at T1 and T2. Data re p sented at T1 and T2. Data are 
pres ted a Mean ± SD in pg/mL. p a repre ent  p-values adjust d for age, ex nd APOE ε4 carri r status. ⱡ represents p-
v lues ob ain from atural log tr nsf med Aβ1-40 or Aβ1-42 c ncent ations o be ter pproximate nor ality. p-values 
<0.05 were consider significant and are prese ed in bold font. 
 D- AA N  D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-40  6.30 ± 7.83 53.87 ± 6.07 0.0 2 0.001 
Aβ1-42 18.02 ± 2.01 11.31 ± 3.02 0.000 9 0.0004 
T2 n = 7 n = 8  





Aβ1- 2 16.85 ± 4.96 11 16 ± 2.79 0.020 ⱡ 0.016 
  
0.362
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T ble 1. P rticipant c r t cs t T1 and T2. Characteri tics including sex, age, expected years to symptom onset 
(EY ) bas d  age at sy pt m onset of biological mutation c rrier parent, APO  ε4 st tus, Mini-Me t l State Examina-
tion (MMSE) Clinical Dement a Rating (CDR) sca  sco es, history f stroke, cerebrospinal fluid (CSF) Aβ1-40 lev-
e s, CSF Aβ1-42 leve s and brain Aβ lo d signal have been compared betw en Dutch-typ  hereditary cerebral amyloid 
angiop thy (D-CAA) utati n non-c rr ers (NC ) and pre-symptomatic carriers (MCs) from the same pedigree at T1 and 
T2. Fish r’  xact t st o  lin ar mo el  wer  m loy d as appropriat . CSF Aβ1-42 and Aβ1-40 were measured using the 
INNOTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebio, Ghent, Belgium). Brain Aβ load was 
m ured via positron emission tom graphy and is pr sented s the standard uptake value ratio (SUVR) of the ligand, 
11C Pittsbur  Comp nd B, upt k  in the p cuneus as he gion of interes , with the cerebell r gr y matter as the 
r fer nce r gion. p a epr sents p-value  adjusted for age, sex and APOE ε4 carri r status. p < 0.05 was considered signifi-
ca  and are presented in bold font. 
 D-C A NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 9882.92 ± 307 .97 6971.35 ± 1088.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 618.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load (SUVR, Mean SD) 0.994 ± .064 1.2 8 ± .248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46.57 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± .02 −2.12 ± 4.75 0.785 - 
APOE ε4 (%) 42 86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ -42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load (SUVR, Mean SD) 1.06 ± .034 1.35 ± .25 0.009 0.001 
# SF pa ameters are only presen ed for eve  NCs and six MCs at T1, and for thr e N s and fiv M s at T2, due to CSF 
sample unavailability. St ti tical comparisons of CSF parameters between NCs and MCs w re not conducted for T2 due 
to the small sample size. 
Table 2. Cro s-section l comp rison of plasma Aβ levels between pre-symptom tic D-CAA mut tion carriers and non-
c rriers measured on th  ult ensitiv  Simoa platf rm. Plasma Aβ levels w re compared between D-CAA mutation 
carri nd o -car iers using gen ral li e r models sep at ly  T1 nd T2. Dat  are presented  T1 and T2. Data are 
present d as M an ± SD i pg/mL.  a pr sents p-values adjuste  for age, sex and APOE ε4 car ier s atus. ⱡ represents p-
values ob ained fr m n tu l l g tr sformed Aβ1-40 r Aβ1-42 concentrations to bett  approximate normality. -values 
<0.05 we con idere  significa  and are presented in bold font. 
 D-CAA NC D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-4   66.30 ± 7 3 53.87 ± 6.07 0. 02 0.001 
Aβ1-42 18.02 ± 2 11.31 ± 3.02 0.00 9 0.0004 
T2 n = 7 n = 8  





Aβ1-42 16.85 ± 4.9 11.16 ± 2.79 0.02  ⱡ 0.016 
  
0.526
Int. J. Mol. Sci. 2021, 22, 2931 5 of 12 
 
Tab e 1. Participant haracter stic at T1 and T2. Characteristics including sex, age, ex ected years to symptom onset 
( YO) b sed o  age at symp om onse  of biologic l mutatio  carrier parent, APOE ε4 s us, Min -Mental State Examina-
on (MM E scores, Clinical m ntia Rati g (CDR) scale scores, hist ry of strok , cerebrospinal fluid (CSF) Aβ1-40 lev-
ls, CSF Aβ1-42 l vels and b in Aβ load sign l ave be  co pared between Dutch-type hered tary cerebral amyloid 
ang opathy (D-CAA  muta ion on-carriers (NCs) and pr - ymptomatic carriers (MCs) from the same pedigree at T1 and 
T2. F she ’s exact t st or linear models we employ d as appropriat . CSF Aβ1-42 and Aβ1-40 wer measured using the 
I  - I ( - 0) an  INNOTEST β-AMYLOID(1-42) ELIS  (Fujirebio, Ghent, Belgium). Brain Aβ load was 
mea ure  vi posit on emission tomography and is presen ed as the standard uptake valu ratio (SUVR) of the ligand, 
11C Pit sbu gh Compound B, upt ke in the precuneus as th  region of in est, with the cerebellar grey matter as the 
r fer ce r gion. p a represents p-values justed for age, sex and APOE ε4 carrier status. p < 0.05 was considered signifi-
cant and are presented in bold font. 
 D- AA N  D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 4 .5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean  SD)  −6. 9 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 2.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 9882.92 ± 3 76.97 6971.3  ± 1 88.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 6 8.63 ± 2 6 81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load (SUVR, Mean ± SD) 994 ± 0. 64 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 6. 7 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean  SD)  −2.97 ± 7.02 −2.12 ± 4.75 0.785 - 
APOE ε4 (%) 42.86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/mL; Mean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load (SUVR, Mean ± SD) 1. 6 ± 34 1.35 ± 0.25 0.009 0.001 
# CSF aramete s a e only pre nted for seven NCs and six MCs at T1, an  for three NCs and five MCs at T2, due to CSF 
sampl  n vailability. Sta i tical mparisons of CSF pa ameters bet een NCs a  MCs were not conducted for T2 due 
to the small sample size. 
T ble 2. C oss-s c nal co p ris  of lasma Aβ levels betwee pre-sy tomatic D-CAA mutation carriers and non-
carri rs m asured o th ult sensitiv Si oa platform. Plasma Aβ levels were compared be ween D-CAA mutation 
c rrier   on-c ri s using gen r l linear models separately t T1 and T2. Data are presented at T1 and T2. Data are 
pres nte  a Me n ± SD i  pg/mL. p a represent p-values dju ted for ag , s x and APOE ε4 carrier status. ⱡ represents p-
valu s btained fr m natural log r sf med Aβ1-40 or Aβ1-42 concent ations to better approximate normality. p-values 
<0.05 were consi e d sig ificant and are presented in bold font. 
 D-CAA NC D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-4   66.30 ± 7.83 53.87 ± 6.07 .002 0.001 
Aβ1-42 18.02 ± 2. 1 11.31 ± 3.02 0. 0009 0.0004 
T2 n = 7 n = 8  
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Table 1. Participant characteristics at T1 and T2. Characteristics including sex, age, expected years to symptom onset 
(EYO) based on age at symptom onset of biological mutation carrier parent, APOE ε4 status, Mini-Mental State Examina-
tion (MMSE) scores, Clinical Dementia Rating (CDR) scale scores, history of stroke, cerebrospinal fluid (CSF) Aβ1-40 lev-
els, CSF Aβ1-42 levels and brain Aβ load signal have been compared between Dutch-type hereditary cerebral amyloid 
angiopathy (D-CAA) mutation non-carriers (NCs) and pre-symptomatic carriers (MCs) from the same pedigree at T1 and 
T2. Fisher’s exact test or linear models were employed as appropriate. CSF Aβ1-42 and Aβ1-40 were measured using the 
INNOTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebio, Ghent, Belgium). Brain Aβ load was 
measured via positron emission tomography and is presented as the standard uptake value ratio (SUVR) of the ligand, 
11C Pittsburgh Compound B, uptake in the precuneus as the region of interest, with the cerebellar grey matter as the 
reference region. p a represents p-values adjusted for age, sex and APOE ε4 carrier status. p < 0.05 was considered signifi-
cant and are presented in bold font. 
 D-CAA NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/ L; ean ± SD) # 9882.92 ± 3076.97 6971.35 ± 1088.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 618.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load (SUVR, Mean ± SD) 0.994 ± 0.064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46.57 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.75 0.785 - 
APOE ε4 (%) 42.86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/ L; ean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load (SUVR, Mean ± SD) 1.06 ± 0.034 1.35 ± 0.25 0.009 0.001 
# CSF parameters are only presented for seven NCs and six MCs at T1, and for three NCs and five MCs at T2, due to CSF 
sample unavailability. Statistical comparisons of CSF parameters between NCs and MCs were not conducted for T2 due 
to the small sample size. 
Table 2. Cross-sectional comparison of plasma Aβ levels between pre-symptomatic D-CAA mutation carriers and non-
carriers measured on the ultrasensitive Simoa platform. Plasma Aβ levels were compared between D-CAA mutation 
carriers and non-carriers using general linear models separately at T1 and T2. Data are presented at T1 and T2. Data are 
presented as Mean ± SD in pg/mL. p a represents p-values adjusted for age, sex and APOE ε4 carrier status. ⱡ represents p-
values obtained from natural log transf r ed Aβ1-40 or Aβ1-42 concentrations to better approximate normality. p-values 
<0.05 were considered significant and are presented in bold font. 
 D-CAA NC D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-40  66.30 ± 7.83 53.87 ± 6.07 0.002 0.001 
Aβ1-42 18.02 ± 2.01 11.31 ± 3.02 0.00009 0.0004 
T2 n = 7 n = 8  





Aβ1-42 16.85 ± 4.96 11.16 ± 2.79 0.020 ⱡ 0.016 
  
0.290
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Table 1. P rticipant characteristics at T1 and T2. Characteristics including s x, age, expected years to symptom onset 
(EYO) based on age at symptom onset of b logical mutation carrier parent, APOE ε4 status, Mini-Mental State Examina-
tion (MMSE) scores, Clinical Dementia R ting (CDR) cale scores, histo y of troke, cerebrospinal fluid (CSF) Aβ1-40 lev-
els, CSF Aβ1-42 levels an brain Aβ load signal hav  be n compared between Dutch-type hereditary cerebral amyloid 
angiopathy (D-CAA) mutation non-carrie s (NCs) and pre-symptomatic carriers (MCs) from th same pe igree at T1 and 
T2. Fisher’s xact test or linear odels were employed as appropriate. CSF Aβ1-42 and Aβ1-40 were measured using the 
INNOTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebio, Ghent, Belgium). Brain Aβ load was 
measured via positron emission tomog aphy and is prese ted as the standard uptake value ratio (SUVR) of the ligand, 
11C Pittsburgh Compou d B, uptake in the precuneus as th  region of inter st, with th  cereb llar grey matter as the 
reference region. p a represent  p-values adjusted for age, sex nd APOE ε4 carrier st tus. p < 0.05 was considered signifi-
cant and are prese ed in bold font. 
 D-CAA NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/ L; ean ± SD) # 882.92 ± 3076.  971.35 ± 1 88.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 618.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load ( UVR, Mean ± SD) 0.994 ± 0.064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46.57 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.7 0.785 - 
APOE ε4 (%) 42.86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/ L; ean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load ( UVR, Mean ± SD) 1.06 ± 0.034 1.35 ± 0.25 0.009 0.001 
# CSF paramet rs are only pr sented for seven NCs and six MCs at T1, and for thr e NCs and five MCs at T2, due to CSF 
sample unava lability. Statistical comparisons of CSF parameters between NCs and MCs were n t conducted for T2 due 
to the small sample size. 
Table 2. Cr ss-sectio al comparison of plasma Aβ lev l  between pre-sympto a ic D-CAA mutatio  carriers and non-
carriers measured on th ultrasensitive Simoa platform. Plasma Aβ levels were compared between D-CAA mutation 
carrie s and non-carriers using general linear models separately at T1 and T2. Data are presented at T1 and T2. Data are 
presented as Mean ± SD in pg/mL. p a represent  p-values adjusted for age, sex nd APOE ε4 carri r status. ⱡ represents p-
values ob ained from natural log transf med Aβ1-40 or Aβ1-42 c ncent atio s to be ter approximate no mali y. p-values 
<0.05 were considered significant and are prese ed in bold font. 
 D-CAA NC D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-40  66.30 ± 7.83 53.87 ± 6.07 0.0 2 0.001 
Aβ1-42 18.02 ± 2.01 11.31 ± 3.02 0.000 9 0.0004 
T2 n = 7 n = 8  





Aβ1-42 16.85 ± 4.96 11.16 ± 2.79 0.020 ⱡ 0.016 
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Table 1. P rticipant characteristics at T1 a d T2. Characteris ics including s x, age, expected years to symptom onset 
(EYO) based n age at symptom ons t of b logical muta ion carrier parent, APOE ε4 status, Mini-Mental State Examina-
tion (MMSE) scores, Clinical Dementia R ting (CDR) cal scores, histo y of troke, cerebrospinal fluid (CSF) Aβ1-40 lev-
els, CSF Aβ1-42 levels an brain Aβ load signal hav  be n compared between Dutch-type hereditary cerebral amyloid 
a giop thy (D-CAA) mutation non-carrie s (NCs) and pre-sy ptomatic carr e s (MCs) from th same pe igree at T1 and 
T2. Fisher’s xact test or line r dels were employed as appropriate. CSF Aβ1-42 a d Aβ1-40 were measured using the 
INNOTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebi , Ghent, Belgium). Brain Aβ load was 
measured via positron emission tomog aphy nd is prese ted as the standard uptake value ratio (SUVR) of the ligand, 
11C Pittsburgh Compou d B, uptake i  the precuneus as th  region of inter st, with th  cereb llar grey matter as the 
referenc  region. p a represent  p-values adjusted fo age, ex nd APOE ε4 carrier st tus. p < 0.05 was considered signifi-
cant and are prese ed in bold font. 
 D-C A NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/ L; ean ± SD) # 882.92 ± 3076.  971.35 ± 1 88.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 6 8.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load ( UVR, Mean ± SD) 0.994 ± 0.064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46. 7 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.7 0.785 - 
APOE ε4 (%) 42.86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 1 0 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/ L; ean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load ( UVR, ean ± SD) 1.06 ± 0.034 1.35 ± 0.25 0.009 0.001 
# CSF paramet rs are only pr sented for seven NCs and six MCs at T1, and for thr NCs and five MCs at T2, due to CSF 
s mple unava lability. Statistical comparisons of CSF paramet rs be ween NCs and MCs were n t conducted for T2 due 
to the small sample size. 
Table 2. Cr s -sectio al compariso  of plas a Aβ lev l  between pre-sympto a ic D-CAA mutatio  carriers and non-
c rriers measured on th ultrasensitive Simoa platfor . Plasma Aβ levels were compared between D-CAA mutation 
carrie s and non-carriers using general linear models separately at T  and T . Data re p sented at T1 and T2. Data are 
presented as Mean ± SD in pg/mL. p a represent  p-values adjusted for age, ex nd APOE ε4 carri r status. ⱡ represents p-
values ob ain from natural log transf med Aβ1-40 or Aβ1-42 c ncent ations o be ter ap roximate normality. p-values 
<0.05 were consider significant and are pr e ed in b ld font. 
 D-CAA N  D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-40  66.30 ± 7.83 53.87 ± 6.07 0.0 2 0.001 
Aβ1-42 18.02 ± 2.01 11.31 ± 3.02 0.000 9 0.0004 
T2 n = 7 n = 8  





Aβ1- 2 16.85 ± 4.96 11 16 ± 2.79 0.020 ⱡ 0.016 
  
0.584 0.159 0.436 0.264
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Table 1. Participant ch ract ristics at T1 and T2. Characteristics including sex, age, expected years to symptom onset 
(EY ) bas d on age at sy ptom onset of biological mutation carrier parent, APOE ε4 status, Mini-Mental State Examina-
tion (MMSE) scores, Clinical Dementia Rating (CDR) sca  scores, history of stroke, cerebrospinal fluid (CSF) Aβ1-40 lev-
els, CSF Aβ1-42 leve s and brain Aβ lo d signal have been compared between Dutch-type hereditary cerebral amyloid 
angiop thy (D-CAA) mutati n non-c rriers (NCs) and pre-symptomatic carriers (MCs) from the same pedigree at T1 and 
T2. Fish r’s exact t st o  linear mo el  wer  mployed as appropriate. CSF Aβ1-42 and Aβ1-40 were measured using the 
IN OTEST β-AMYLOID(1-40) and INNOTEST β-AMYLOID(1-42) ELISA (Fujirebio, Ghent, Belgium). Brain Aβ load was 
m ured via positron emission tom graphy and is presented as the standard uptake value ratio (SUVR) of the ligand, 
11C Pittsbur  Compound B, upt ke in the precuneus as the region of interest, with the cerebellar grey matter as the 
refer nce region. p a epresents p-value  adjusted for age, sex and APOE ε4 carrier status. p < 0.05 was considered signifi-
cant and are presented in bold font. 
 D-CAA NC D-CAA MC p p a 
T1 
N 8 9 - - 
Sex (M/F) 3/5 3/6 1.00 - 
Age (Mean ± SD) 43.5 ± 6.57 44.11 ± 4.31 0.822 - 
EYO (years; Mean ± SD)  −6.09 ± 6.43 −5.27 ± 4.30 0.759 - 
APOE ε4 (%) 37.5 22.2 0.620 - 
MMSE (Mean ± SD) 28.63 ± 1.60 28.67 ± 1.41 0.955 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/ L; ean ± SD) # 9882.92 ± 3076.97 6971.35 ± 1088.65 0.051 0.039 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 618.63 ± 206.81 311.67 ± 154.85 0.012 0.007 
Brain Aβ load (SUVR, Mean SD) 0.994 ± 0.064 1.268 ± 0.248 0.009 0.011 
T2 
N 7 8 - - 
Sex (M/F) 2/5 2/6 1.00 - 
Age (Mean ± SD) 46.57 ± 7.21 46.25 ± 4.65 0.830 - 
EYO (years; Mean ± SD)  −2.97 ± 7.02 −2.12 ± 4.75 0.785 - 
APOE ε4 (%) 42.86 25 0.608 - 
MMSE (Mean ± SD) 28.71 ± 1.38 28.63 ± 0.92 0.883 - 
CDR global = 0 (%) 100 100 - - 
Stroke (%) 0 0 - - 
CSF Aβ1-40 (pg/ L; ean ± SD) # 7483.03 ± 1454.50 3933.53 ± 1993.14 - - 
CSF Aβ1-42 (pg/mL; Mean ± SD) # 1078.44 ± 162.86 346.61 ± 147.11 - - 
Brain Aβ load (SUVR, Mean SD) 1.06 ± 0.034 1.35 ± 0.25 0.009 0.001 
# SF parameters are only presented for seven NCs and six MCs at T1, and for three NCs and five MCs at T2, due to CSF 
sample unavailability. Stati tical comparisons of CSF parameters between NCs and MCs were not conducted for T2 due 
to the small sample size. 
Table 2. Cross-section l comparison of plasma Aβ levels between pre-symptomatic D-CAA mutation carriers and non-
c rriers measured on th  ult asensitiv  Simoa platform. Plasma Aβ levels were compared between D-CAA mutation 
carriers nd no -carriers using gen ral line r models sep ately at T1 and T2. Data are presented at T1 and T2. Data are 
present d as M an ± SD i  pg/mL.  a presents p-values adjusted for age, sex and APOE ε4 carrier status. ⱡ represents p-
values ob in d fr m n tu al log transformed Aβ1-40 or Aβ1-42 concentrations to better approximate normality. p-valu s 
<0.05 were considered significant and are pres nted in bold font. 
 D-CAA NC D-CAA MC p p a 
T1 n = 8 n = 9  
Aβ1-4   66.30 ± 7.83 53.87 ± 6.07 0.002 0.001 
Aβ1-42 18.02 ± 2. 1 11.31 ± 3.02 0.00009 0.0004 
T2 n = 7 n = 8  





Aβ1-42 16.85 ± 4.96 11.16 ± 2.79 0.020 ⱡ 0.016 
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Figure 2. Longitudinal changes in plasma Aβ1-40 and Aβ1-42 levels between D-CAA mutation non-carriers and carriers.
Longitudinal measures of plasma Aβ1-40 and Aβ1-42 levels are presented for D-CAA mutation non-carriers (NCs, blue,
n = 7) and carriers (MCs, red, n = 8). Plasma Aβ1-40 and Aβ1-42 levels have been plotted against the expected years to
symptom onset (EYO), calculated from the difference of age of the participant and the age at symptom onset of the study
pedigree.
3.6. Longitudinal Changes in Plasma Aβ Concentrations Employing the xMAP Technology
No statistically significant effect on plasma Aβ1-40 concentrations were observed over
time (T1 to T2), including pairwise comparisons in MCs or NCs, and Time * Mutation status
interactions, before and after adjusting for covariates, age, sex and APOE ε4 genotype
(Supplementary Table S2).
Longitudinal analyses revealed that Aβ1-42 concentrations decreased over time (T1 to
T2) with a trend towards significance, before (p = 0.066) and after (p = 0.084) adjusting for
covariates, age, sex and APOE ε4 genotype, wherein pairwise comparisons showed signifi-
cantly decreased mean plasma Aβ1-42 concentrations in MCs (p < 0.05, Supplementary
Table S2). No statistically significant effect of time on plasma Aβ1-42 in NCs was observed
before or after adjusting for covariates. Time * Mutation status interaction revealed no
significant differences in plasma Aβ1-42 changes between MCs and NCs, either before
or after adjusting for potential confounding variables age, sex and APOE ε4 genotype
(Supplementary Table S2).
4. Discussion
The current study is the first to report on plasma Aβ1-40 and Aβ1-42 alterations
between pre-symptomatic D-CAA MCs (i.e., prior to stroke and cognitive impairment) and
NCs from the same pedigree, using the ultrasensitive Simoa technology, wherein lower
plasma Aβ1-40 and Aβ1-42 levels were observed in MCs compared to the NCs in line with
our hypothesis. These observations were consistent at both study timepoints which were at
least three years apart. Findings from these cross-sectional analyses using the ultrasensitive
Simoa technology platform suggest that plasma Aβ1-40 and Aβ1-42 may serve as potential
candidates for a CAA diagnostic biomarker panel, although further validation studies are
necessary in sporadic CAA.
While our cross-sectional observations of lower plasma Aβ1-40 and Aβ1-42 in MCs
compared to NCs within the current study were consistent at two independent timepoints
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using the ultrasensitive Simoa technology platform, previous studies investigating plasma
Aβ1-40 and Aβ1-42 in CAA (D-CAA and sporadic-CAA) have been inconsistent. One study
reported no significant difference in plasma Aβ1-40 levels but significantly lower plasma
Aβ1-42 levels in D-CAA MCs compared to NCs [16], while a study on sporadic CAA
individuals comprising 80% probable CAA and 20% definite CAA, reported no significant
difference in plasma Aβ1-40 and Aβ1-42 concentrations compared to controls [15], and
yet another study reported significantly higher plasma Aβ1-40 and Aβ1-42 in probable
CAA compared to controls [17]. These contrasting observations could be attributed to the
sensitivity of the assays employed to measure plasma Aβ concentrations. For example,
plasma Aβ1-40 and Aβ1-42 concentrations measured on the xMAP platform, as employed
by Hernandez-Guillamon and colleagues [17], when used in participants within the present
study (at both timepoints, T1 and T2), also did not appear to be significantly different
cross-sectionally after adjusting for covariates (Supplementary Figure S1, Supplementary
Table S1), therefore highlighting the differences between assay platforms. However, it is
also important to note that participants in the present study had no history of stroke and no
cognitive impairment, as opposed to participants from the aforementioned studies, which
may have contributed to the differences in our observations, since stroke related cognitive
impairment may be associated with changes in Aβ levels [24].
The lower levels of plasma Aβ1-40 and Aβ1-42 and higher brain Aβ load observed
in D-CAA mutation carriers have been posited to be attributed to altered processing and
transport of Aβ, wherein the D-CAA mutation impairs Aβ elimination from the brain
by reducing transport across the blood–brain barrier (BBB) and the vascular drainage
pathways [16,25]. CAA patients have been previously shown to have higher microvascular
expression of the receptor for advanced glycation end products (RAGE) and reduced low-
density lipoprotein receptor-related protein 1 (LRP1) expression, which regulate the influx
and efflux, respectively, of Aβ across the BBB [26,27]. Therefore, the results of this study
are consistent with previous literature that has demonstrated impairment of Aβ transport
mechanisms between brain and periphery in CAA. Additionally, the D-CAA MCs show
diffuse-type plaque in cerebral cortex, and therefore lower plasma Aβ1-42 levels in the
MCs could be affected by the status of cerebral beta amyloidosis [28].
Longitudinal changes in mean plasma Aβ1-40 and Aβ1-42 concentrations, measured
using the Simoa and xMAP platforms, respectively, were observed to significantly decrease
with time in MCs, but not in NCs. These observations may reflect increased D-CAA
pathophysiology with time, i.e., further vascular or cerebral Aβ deposition with time in D-
CAA cases. However, a larger sample size with more datapoints is required to confirm this.
Furthermore, observations of significantly declining plasma Aβ1-40 in MCs employing the
Simoa platform and significantly declining plasma Aβ1-42 in MCs employing the xMAP
platform, suggest that platform- and/or antibody- or isoform-specific differences might
exist, however, further validation studies are required.
A limitation within the current study is its modest sample size. However, the current
study has several strengths including the utilisation of NC and MC plasma samples
from the same D-CAA pedigree, the validation of lower plasma Aβ1-40 and Aβ1-42
concentrations in D-CAA MCs cross-sectionally at two timepoints (T1 and T2), and the
employment of an ultrasensitive platform for the measurement of plasma Aβ1-40 and
Aβ1-42 concentrations.
An important consideration from the findings of this study would be, whether ob-
servations from the Dutch-CAA cases will be applicable to sporadic CAA cases, in the
context of a biomarker, within the presymptomatic phase. Sporadic CAA may be more
heterogeneous, wherein faulty vascular/perivascular clearance may be more important
than overproduction of Aβ in some sporadic CAA. Faulty clearance mechanism in sporadic
CAA may be more vulnerable to vascular risk factors such as hypertension or diabetes. Ad-
ditionally, given that clinically most sporadic CAA coexist with AD, it is important to note
that the use of a blood Aβ assay alone is likely to be limited, while a panel of biomarkers
(including Aβ) is more likely to have success, for the diagnosis of pre-symptomatic CAA.
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To conclude, cross-sectional analyses of data obtained from the ultrasensitive Simoa
platform revealed that plasma Aβ1-40 and Aβ1-42 concentrations are lower in pre-symptomatic
D-CAA MCs compared to NCs and longitudinal analyses revealed that plasma Aβ1-40
levels decreased in MC. Additionally, longitudinal analyses of data obtained from the
xMAP platform revealed that plasma Aβ1-42 levels are decreased in MCs. While platform
differences might exist, findings from this study suggest that plasma Aβmay add value
to a panel of biomarkers for the diagnosis of pre-symptomatic CAA, however, further
validation studies in larger samples sets are required and future validation studies are
necessary in sporadic-CAA.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-006
7/22/6/2931/s1.
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